Divis Labs

Gainers & Losers: Top 10 stocks that moved the most on August 25

At close, the Sensex was up 329.06 points or 0.40 percent at 81,635.91, and the Nifty was up 97.65 points or 0.39 percent at 24,967.75. About 1830 shares advanced, 2169 shares declined, and 178 shares unchanged.

Gainers & Losers: Top 10 stocks that moved the most on August 22

At close, the Sensex was down 693.86 points or 0.85 percent at 81,306.85, and the Nifty was down 213.65 points or 0.85 percent at 24,870.10. About 1695 shares advanced, 2205 shares declined, and 144 shares unchanged.

Divis Laboratories shares slip 4% as Entresto patent setback clouds growth outlook

Divis Laboratories share price: Entresto is considered a cornerstone of Divi’s innovator-driven custom synthesis portfolio, contributing close to 40 percent of the segment’s revenue.

Divi’s Lab: Operating leverage lifts margin profile

While pricing erosion remains a challenge for generic APIs, new opportunities for generic molecules will unfold in FY26. A lot of drug developments held up during COVID-19 are now getting fast-tracked

Divi's Labs shares soar 5% as investors cheer solid Q3 earnings

Divi's Labs delivered well rounded earnings growth in Q3, beating expectations on all major parameters--profit, revenue and profitability.

Brokerage Radar: Divi's Labs, Paytm receive positive calls but LIC Housing Fin gets mixed calls

Check out the latest brokerage calls and analyst comments on the stocks in action today. Our coverage includes LIC Housing Finance, Divi's Labs, Gland Pharma, ONGC and Aster DM, among others.

Zomato & Jio Financial: Next Big Entrants to Nifty 50?

Could Zomato and Jio Financial Services be the next to join the Nifty 50 index? Market experts are buzzing about potential inclusions and exclusions in the upcoming index reshuffle. Zoya Springwala discusses how these changes will come into place, what this reshuffle means for BPCL and Britannia Industries, and how stocks are selected to join the benchmark index.

Citi sees any sharp correction in Divi's Labs shares as a strong buying opportunity

Analysts at Citi are not too concerned as they believes that even while the passage of the Biosecure Act appears to have been delayed, its thesis remains intact for Divi's Labs.

Uncertainty over US Biosecure Act weighs heavy on Divi's Labs, Neuland Labs, Piramal Pharma

The US Biosecure Act seeks to limit the dominance of Chinese players in the US biotech industry, creating new opportunities for Indian companies to expand their presence.

Divi's Labs remains Citi's top pharma pick, sees 15% more upside

Citi remains bullish over Divi's expanding portfolio in its contrast media business, seeing the company as structurally as well as tactically well-positioned.

Divi's Labs Q2 Results: Net profit rises 46% to Rs 510 crore, revenue at Rs 2,338 crore

The pharma major's EBITDA rose almost 50 percent to Rs 716 crore.

Gainers & losers: Stocks and sectors that moved the most on October 9

Selling in the last hour of trade pulled the Nifty and Sensex sharply off its day's high to close near the flatline.

Divi's Labs hits record high after Citi initiates 'buy' call with most bullish price target

Citi sees Divi's Labs as the key beneficiary of the trend toward supply chain diversification. As a result, they became the first brokerage to forecast that the drugmaker's stock would surpass the Rs 6,000 mark.

Divi's Labs plans to foray into peptide fragments, expects API pricing to stabilise

API prices have remained under pressure for the past two years on the back of inventory destocking from Chinese companies post-COVID.

Divis Labs Q1 Results: Net profit rises 21% to Rs 430 crore, misses estimates

The low base of the last fiscal and strong sales in the custom synthesis segment helped drive profit and revenue growth for Divis.